These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 23908119)

  • 21. Catecholamines regulate tumor angiogenesis.
    Chakroborty D; Sarkar C; Basu B; Dasgupta PS; Basu S
    Cancer Res; 2009 May; 69(9):3727-30. PubMed ID: 19383906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-angiogenic therapies: from theory to practice].
    Bidart M; Berger F; Pelletier L
    Ann Biol Clin (Paris); 2013; 71(5):527-35. PubMed ID: 24113438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of angiogenesis in cancers.
    Pang RW; Poon RT
    Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-angiogenesis in cancer therapy: Hercules and hydra.
    Bellou S; Pentheroudakis G; Murphy C; Fotsis T
    Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor angiogenesis revisited: Regulators and clinical implications.
    Ronca R; Benkheil M; Mitola S; Struyf S; Liekens S
    Med Res Rev; 2017 Nov; 37(6):1231-1274. PubMed ID: 28643862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of selected patents for cancer therapy targeting tumor angiogenesis.
    Kirstein MN; Moore MM; Dudek AZ
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):153-61. PubMed ID: 18221033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic therapy for cancer: an update.
    Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
    Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.
    Carmeliet P; De Smet F; Loges S; Mazzone M
    Nat Rev Clin Oncol; 2009 Jun; 6(6):315-26. PubMed ID: 19483738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis.
    Song K; Wu H; Rahman HN; Dong Y; Wen A; Brophy ML; Wong S; Kwak S; Bielenberg DR; Chen H
    Cell Mol Life Sci; 2017 Feb; 74(3):393-398. PubMed ID: 27572288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor: biology and therapeutic applications.
    Ho QT; Kuo CJ
    Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
    Maes H; Olmeda D; Soengas MS; Agostinis P
    FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-VEGF therapies in the clinic.
    Meadows KL; Hurwitz HI
    Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vessel pruning or healing: endothelial metabolism as a novel target?
    Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
    Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
    Cao Y; Zhong W; Sun Y
    Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
    Olejarz W; Kubiak-Tomaszewska G; Chrzanowska A; Lorenc T
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.